Introduction {#sec1}
============

*L3MBTL1* is the human homolog of the *Drosophila* tumor suppressor gene, l(3)mbt ([@bib48]). The *L3MBTL1* gene is located on the long arm of chromosome 20, within the region that is commonly deleted in hematologic malignancies ([@bib4; @bib5]). The crystal structure of the three MBT domains in human L3MBTL1 exhibited a triple-bladed propeller-like structure ([@bib45]), and subsequent studies showed that L3MBTL1 binds to mono- and di-methylated lysines on histones H1 (H1K26) and H4 (H4K20) via the second MBT repeat ([@bib18; @bib23]). Upon recruitment to the chromatin, L3MBTL1 generally functions as a chromatin compactor and transcriptional repressor ([@bib8; @bib18; @bib41]). Despite its role in affecting chromatin structure, the function of L3MBTL1 in human hematopoiesis had largely remained elusive. Our group and others have demonstrated that knockdown (KD) of L3MBTL1 results in the enhanced erythroid differentiation of human hematopoietic stem/progenitor cells (HSPCs) ([@bib3; @bib33]), which suggests that haploinsufficiency of *L3MBTL1* contributes to 20q- myeloproliferative neoplasms.

In the human embryonic stem cells (hESCs), depletion of L3MBTL1 leads to spontaneous trophoblastic differentiation, a phenotype that mirrors BMP4-treated hESCs ([@bib17]). BMP4 is a critical signaling molecule ([@bib19]), directing the hematopoietic fate from mesoderm during development ([@bib20; @bib21; @bib25; @bib27; @bib30; @bib34; @bib50]). In particular, exogenous BMP4 can augment the hematopoietic differentiation of hESCs, and substantially increase the proportion of committed hematopoietic cells generated from induced pluripotent stem cells (iPSCs) ([@bib16]). It is now believed that a mixture of trophoblast- and mesoderm-committed cells emerges in response to BMP4 exposure ([@bib6]). BMP4 engages the BMP receptor, promoting the interaction between its two subunits (BMPR-IA or IB and II) and triggering the phosphorylation of SMAD1, SMAD5, or SMAD8 prior to their association with SMAD4 and their translocation to the nucleus ([@bib26]).

Ectopic BMP signaling activates the primitive erythroid program, while inhibiting the pathway blocks ventral blood island formation in *Xenopus* ([@bib51]). This suggests that BMP signaling may represent a critical influence on erythroid differentiation, in addition to its role in mesoderm specification ([@bib37]). In the human adult hematopoietic system, BMP4 mediates regeneration under stress conditions ([@bib22; @bib42]) and the differentiation of hematopoietic progenitors into erythroid and myeloid lineages ([@bib12; @bib13]). BMP signaling also has been implicated in the malignant transformation of HSPCs: the recently discovered, cryptic recurring translocation in pediatric acute megakaryoblastic leukemia, which leads to fusion of the *CBFA2T3* and *GLIS2* genes, alters the expression of BMP target genes, leading to enhanced self-renewal of HSPCs ([@bib14]).

Here, we demonstrate that depletion of L3MBTL1 primes human pluripotent stem cells to undergo hematopoietic fate commitment. We observed increased clonogenic hematopoietic potential in the knocked down cells compared to controls and the early emergence of a primitive CD45^−^CD31^+^CD34^+^ cell population thought to be hemogenic precursors. Comprehensive assessment of lineage fates in L3MBTL1-KD pluripotent stem cells showed decreased expression of endodermal- and ectodermal-specific genes. We also found impaired development of neural progenitors by culturing KD embryoid bodies (EBs) with brain-derived neurotrophic factor (BDNF), which was accompanied by increased expression of hematopoietic surface markers, despite the directive cell culture conditions.

The L3MBTL1-KD cells showed an upregulated SMAD5-mediated transcriptional signature, and we found that L3MBTL1 regulates the expression of SMAD5 and impairs its recruitment to target regulatory regions, in both immature and mature hematopoietic cell populations. Via effects on the erythroid-specific transcription factor, EKLF, L3MBTL1, and SMAD5 control the erythroid differentiation of primary cord blood CD34^+^ cells and hematopoietic cell lines.

Results {#sec2}
=======

KD of L3MBTL1 Primes the Hematopoietic Potential of iPSCs {#sec2.1}
---------------------------------------------------------

The generation of iPSC lines has provided opportunities to understand the fundamental processes of human cell fate decisions in the context of tissue regeneration and human disease. We first observed spontaneous downregulation of *L3MBTL1* expression in a human iPSC line generated from cord blood cells (iCBCs) ([Figures S1](#app3){ref-type="sec"}A--S1C) upon mesodermal differentiation, suggesting that decreased *L3MBTL1* expression is required for mesoderm specification ([Figure 1](#fig1){ref-type="fig"}A). To investigate the role of L3MBTL1 on the specification of hematopoiesis during iPSC differentiation, we knocked down L3MBTL1 using H1P-hygro-EGFP+ lentiviral vectors that express small hairpin RNAs (shRNAs) directed against *L3MBTL1* ([Figure 1](#fig1){ref-type="fig"}B). The subcloned green fluorescent protein (GFP)^+^ colonies showed a marked decrease in L3MBTL1 expression and retained stem cell morphology and stem-cell-related cell surface markers, including TRA-1-81, KLF4, OCT4, and NANOG expression ([Figures S1](#app3){ref-type="sec"}D--S1G). Expression of mesoderm-specific transcription factors (*T*, *TAL1*, *LMO2*, and *RUNX1*) was consistently increased in the KD cells, while key markers for endoderm and ectoderm decreased ([Figure 1](#fig1){ref-type="fig"}C). We observed downregulation of *SOX2* even though the iPSCs maintained self-renewal properties. While consistent with a previous report ([@bib47]), we did find upregulation of SOX3 (data not shown), which also could explain the self-renewal phenotype. Functional assessment of clonogenic hematopoietic progenitors (CFUs) revealed that the lack of L3MBTL1 induced an increase in hematopoietic progenitor cell generation ([Figure 1](#fig1){ref-type="fig"}D). The hematopoietic colonies derived from the L3MBTL1-KD cells were also larger in size (data not shown). CD45^−^CD31^+^CD34^+^ cells, which represent a primitive bipotent endothelial-like precursor population that is exclusively responsible for hematopoietic fate ([@bib46]), were also much more abundant within the L3MBTL1-KD cells compared to controls ([Figure 1](#fig1){ref-type="fig"}E).

Taken together, these findings indicate that lowering L3MBTL1 expression primes hematopoietic development in iPSCs, inducing changes in gene expression that regulate lineage fate divisions driven by specific differentiation-promoting conditions.

Impaired Development of Neural Progenitors in L3MBTL1-KD Pluripotent Stem Cells {#sec2.2}
-------------------------------------------------------------------------------

To assess the neural differentiation potential of the L3MBTL1-KD cells, we generated EBs and cultured them in BDNF-containing conditions that support the development of neural progenitor cells ([Figure 2](#fig2){ref-type="fig"}A, top). While control EBs developed into Nestin^+^ neural precursors and Tuj1^+^ differentiated neurons, L3MBTL1-KD cells showed impaired neural lineage differentiation ([Figure 2](#fig2){ref-type="fig"}A, bottom and right). The impaired generation of neural precursors is not dependent on decreased cell proliferation or increased apoptosis, as we found no significant change in the expression of Ki-67 and Annexin V ([Figures S2](#app3){ref-type="sec"}A and S2B).

To determine whether L3MBTL1-KD EBs still express hematopoietic markers under culture conditions that specifically support neural development, we first assessed CD34 expression using immunofluorescence (IF) and flow cytometry. We found increased CD34 expression in the KD EBs under conditions that generally promote neural fate ([Figure 2](#fig2){ref-type="fig"}B). Given the general impairment of neural differentiation, the expression of CD31 and TAL1, which are expressed in hemato-endothelial progenitors ([@bib36]) but also increased in the KD EBs ([Figure S2](#app3){ref-type="sec"}C), suggests the presence of hemogenic precursors. It is possible that the TAL1^+^ cells in the L3MBTL1-KD are undifferentiated ESCs within a mixture of cell populations that could not undergo neural development under BDNF-mediated culture conditions.

Overall, these data indicate that KD of L3MBTL1 promotes hematopoietic development while impairing neural development.

L3MBTL1 Transcriptionally Represses SMAD5 {#sec2.3}
-----------------------------------------

To investigate the mechanisms underlying the observed effects of L3MBTL1 on stem cell biology, we utilized an unbiased, genome-wide approach to analyze the gene expression profile (GEP) of two independent clones of undifferentiated L3MBTL1-KD iPSCs. We found increased expression of several BMP/SMAD target genes, as well as downregulation of negative regulators of BMP signaling ([Figures 3](#fig3){ref-type="fig"}A and 3B). *ID2* and *ID3* were among the upregulated genes, which are direct targets of BMP4 and regulate HSPC fate decisions ([@bib16; @bib43]). *HHEX* also was upregulated; it is known to regulate globin gene expression during ontogeny and its promoter contains a 71 nucleotide BMP-responsive element (BRE) ([@bib52]). We also found increased expression of *ZFP36L2*, an RNA-binding protein required for BFU-E self-renewal ([@bib53]) (data not shown). Expression of *SMAD7*, which inhibits TGFβ-related signaling ([@bib29]), was downregulated, as were *LEFTY1* and *LEFTY2*, which function as extracellular antagonists of Nodal signaling ([@bib49]).

Analysis of curated pathway gene sets by gene set enrichment analysis (GSEA) showed statistically significant (p \< 0.0002; FDR \< 0.001) enrichment of SMAD targets as well as enrichment of three different sets of hematopoietic stem cell genes ([Figures 3](#fig3){ref-type="fig"}C and [S3](#app3){ref-type="sec"}A). We also found enrichment of hematopoietic (non-stem cell) gene sets and enrichment of hematopoietic transcription factor target gene sets ([Figures S3](#app3){ref-type="sec"}B and S3C). These data, which were obtained from the undifferentiated stage of L3MBTL1-KD iPSCs, show activation of a hematopoietic cell transcriptional program, fully compatible with the phenotype we induced by culturing these cells under hematopoietic-specifying culture conditions. Gene ontology analysis also supported these findings ([Table S1](#app3){ref-type="sec"}).

To identify which SMAD-regulated signaling pathways are triggered by L3MBTL1 depletion, we evaluated the phosphorylation of SMAD1/5 and SMAD2/3, which primarily function downstream of the BMP receptors and the TGFβ, Activin, and Nodal receptors, respectively. We found enhanced SMAD1/5 phosphorylation ([Figure 3](#fig3){ref-type="fig"}D), indicating that L3MBTL1 titrates BMP signaling.

We also found increased SMAD5 ([Figure 3](#fig3){ref-type="fig"}D) and SMAD1 ([Figure S3](#app3){ref-type="sec"}D) expression in the L3MBTL1-KD cells compared to controls. Given the transcriptional repressor functions of L3MBTL1 ([@bib8]), we investigated whether L3MBTL1 directly regulates *SMAD5* and *SMAD1* expression by performing chromatin immunoprecipitation (ChIP) assays. We found recruitment of L3MBTL1 to regulatory regions of the *SMAD5* and *SMAD1* promoters ([Figures 3](#fig3){ref-type="fig"}E and [S3](#app3){ref-type="sec"}E), yet the increase in expression was much higher for SMAD5 than for SMAD1 and correlated with stronger recruitment of L3MBTL1 to the *SMAD5* than to the *SMAD1* target promoter. Consistent with the increased SMAD5 and SMAD1 expression, ChIP experiments in the L3MBTL1-KD cells showed fewer repressive histone marks (i.e., H3K27me3) at the *SMAD5* than at the *SMAD1* promoter ([Figures 3](#fig3){ref-type="fig"}F and [S3](#app3){ref-type="sec"}F).

Regulation of SMAD5 by L3MBTL1 Occurs in Erythroid Cells {#sec2.4}
--------------------------------------------------------

We, and others, have suggested that L3MBTL1 plays an important role in erythroid differentiation of human CD34^+^ HSPCs ([@bib3; @bib33]). We found that downregulation of *L3MBTL1* occurs during normal erythroid differentiation, in a manner similar to that seen during mesodermal differentiation ([Figure 1](#fig1){ref-type="fig"}A). We first assessed the effect of L3MBTL1-KD in iPSC-derived CD34^+^ cells undergoing erythroid differentiation, and observed a marked acceleration in the expression of the erythroid-specific marker GlyA (after 2 days in EPO-induced culture) by flow cytometry in the L3MBTL1-KD cells ([Figure 4](#fig4){ref-type="fig"}A). This was followed by a significant increase in the expression of several erythroid-specific transcription factors, especially *EKLF* ([Figure 4](#fig4){ref-type="fig"}B). We also confirmed this phenotype in β-thalassemic iPSCs ([@bib31]), which we lentivirally infected to express shRNAs targeting *L3MBTL1* ([Figure S4](#app3){ref-type="sec"}A). Similar to the CB-iPSC line, knocking down L3MBTL1 in thalassemic erythroid progeny also increased EKLF expression ([Figure S4](#app3){ref-type="sec"}B) and increased *fetal globin* gene expression compared to controls ([Figure S4](#app3){ref-type="sec"}C).

Ten SMAD-binding motifs were identified within the upstream enhancer, proximal promoter, and intronic enhancer of EKLF using EBs ([@bib1; @bib25]); thus, we investigated whether L3MBTL1 regulates *EKLF* gene expression by SMAD5 in cells that are more mature than pluripotent stem cells. We found SMAD5 at most of these regions using ChIP assays in K562 erythroleukemia cells ([Figure 4](#fig4){ref-type="fig"}C, gray bars), and by retrovirally overexpressing L3MBTL1-HA in K562 cells we found impaired recruitment of SMAD5 to these *EKLF* regulatory regions ([Figure 4](#fig4){ref-type="fig"}C, blue bars). Furthermore, L3MBTL1 overexpression decreased SMAD5 expression in K562 cells ([Figure S4](#app3){ref-type="sec"}D).

When we examined primary cord blood CD34^+^ cells, we found primarily increased expression of *EKLF* among several erythroid-specific genes following KD of L3MBTL1 ([Figure 4](#fig4){ref-type="fig"}D). We also found increased *globin* gene expression in the L3MBTL1-KD CD34^+^ cells ([Figures 4](#fig4){ref-type="fig"}E and [S4](#app3){ref-type="sec"}E) and decreased *globin* expression following overexpression of L3MBTL1 ([Figure 4](#fig4){ref-type="fig"}F). Similar observations were made in K562 cells ([Figures 4](#fig4){ref-type="fig"}G, [S4](#app3){ref-type="sec"}F, and [S4](#app3){ref-type="sec"}G), where we also found an increase in EKLF expression following L3MBTL1-KD ([Figure S4](#app3){ref-type="sec"}H).

Overall, these data indicate that the regulation of SMAD targets by L3MBTL1 occurs in mature erythroid cells as well as pluripotent stem cells; this effect further promotes erythroid differentiation.

Discussion {#sec3}
==========

This study shows that loss of the Polycomb protein L3MBTL1 primes human iPSCs for hematopoietic differentiation and enhances commitment toward the erythroid lineage.

Epigenetic Priming of Hematopoietic Lineage {#sec3.1}
-------------------------------------------

In many biological systems, epigenetic regulation is important for modulating the expression of critical developmental genes ([@bib40]). For example, in hESCs, epigenetic priming of genomic regulatory regions is an important mechanism underlying the early specification of future developmental fates. During the erythroid differentiation of HSPCs, many genes involved in development and differentiation lose their H3K27me3 mark, and a fraction of them become enriched with H3K4me1 and H3K9me1 marks, suggesting that these genes are poised for activation during the differentiation process ([@bib7; @bib10]). Several epigenetic regulatory mechanisms control gene induction and repression during erythroid development ([@bib15]). The enhancer-mediated recruitment of JMJD3 leads to exclusion of the repressive Polycomb repressive complex 2 (PRC2) from the poised alpha-globin promoter in erythroid cells ([@bib44]). The L3MBTL1-KD undifferentiated iPSCs display a GEP that predicts the precocious generation of hemogenic precursors and an expansion of induced hematopoietic cells under culture conditions that support hematopoietic cell specification. These changes in gene expression include upregulation of BMP/SMAD targets and downregulation of inhibitors of this signaling pathway, which may mediate, at least in part, a trophectoderm versus epiblast decision, as well as a mesoderm versus ectoderm decision, and finally a non-neural ectoderm versus neural ectoderm decision. Accordingly, the KD iPSCs cannot efficiently generate neural progenitors under conditions that allow activation of the BMP/SMAD-signaling pathway. The impaired neural development that we observed in L3MBTL1-KD cells supports the observation that activation of BMP4 signaling is inhibitory to the development of non-hematopoietic lineages ([@bib11]). Consistent with our findings, using two inhibitors of SMAD signaling, Noggin and SB431542, one can induce the rapid and nearly complete conversion of \>80% of hESCs to neural cells ([@bib9]). This epigenetic silencing mechanism involving L3MBTL1 also may underlie previous findings in the L3MBTL1-KD hESCs, which are able to generate neural progenitors when cultured with SB431542 and dorsomorphin, strong inhibitors of the SMAD-signaling pathways, and spontaneously differentiate toward the trophoblast lineage (mirroring the BMP4-treated hESCs) ([@bib17]).

It is possible that a feedback regulatory mechanism of L3MBTL1 occurs upon the addition of extrinsic BMP4, as downregulation of L3MBTL1 expression occurs during mesodermal specification ([Figure 1](#fig1){ref-type="fig"}A). This could mean not only that mesodermal differentiation requires silencing of L3MBTL1, but also that BMP4 regulates L3MBTL1 expression, especially given that changes in culture conditions (days 6--10) restore the initial levels of L3MBTL1 expression.

An enhanced differentiation toward other non-hematopoietic mesodermal lineages, or non-neural ectoderm lineages, cannot be excluded in the L3MBTL1-KD cells. Indeed, while GSEA primarily supported our findings ([Figure S3](#app3){ref-type="sec"}B), we also found significant enrichment of gene sets related to targets of other PcG proteins in ESCs, such as SUZ12 ([@bib32]). These epigenetic signatures regulate establishment of expression programs for ESC differentiation. In fact, given the diverse signaling pathways that govern hematopoietic cell development, it is likely that additional pathways contribute to hematopoiesis at later stages of differentiation.

Transcriptional Networks and Signaling Pathways in Lineage Specification {#sec3.2}
------------------------------------------------------------------------

Developmental decisions require the integration of a variety of signaling pathways, and transitions between poised and active regulatory states are closely integrated with various developmental signals. There appears to be a close relationship between core lineage regulators and signaling pathway outputs. Hence, the genomic binding of transcriptional effectors of TGFβ, BMP, and WNT pathways not only follows the binding of master regulators of lineage identity, but can be broadly redirected by the overexpression of a regulatory or lineage-specifying factor for another cell type ([@bib28; @bib42]).

Our study shows that modulation of L3MBTL1 expression directs lineage-specific gene expression by regulating the expression of SMAD5 and its recruitment to critical regulatory regions, such as the erythroid transcription factor EKLF, allowing it to regulate globin gene expression.

Combinatorial crosstalk among transcription factors is essential to direct the lineage specification of HSPCs. In agreement with larger maps of combinatorial interactions among transcription factors ([@bib35]), our work implies that lineage specification is not completely determined by tissue-specific transcription factors (such as EKLF), but can be modulated by crosstalk with transcription factors that are broadly expressed (like SMAD5). A similar effect is seen in the regulation of monocyte differentiation by SMAD3 (generally expressed) and FLI1 (whose expression is more restricted primarily to macrophage-related tissues, such as spleen and lymph nodes) ([@bib35]).

We identified SMAD5 as a target of L3MBTL1 and showed that L3MBTL1 represses its ability to drive target gene expression. KD of SMAD5 impairs maintenance of the erythroid program ([@bib13; @bib24; @bib27]), whereas upregulation of EKLF, a crucial erythroid-specific transcription factor ([@bib2; @bib38]), occurs in response to BMP4 treatment in EBs ([@bib1; @bib25]). Here we demonstrated the recruitment of SMAD5 to these binding sites in definitive hematopoietic cells and the regulation of EKLF expression and function via L3MBTL1.

As a readout of EKLF expression and function, we evaluated globin gene expression in definitive hematopoietic cells, which was inversely correlated with L3MBTL1 expression. Increased understanding of how genetic and epigenetic programs regulate different stages of red blood cell (RBC) development may enable large-scale production of functional RBCs from ESCs and iPSC-derived cells. Hopefully, a deeper understanding of the mechanisms regulating erythropoiesis will result in the development of drugs that are useful in treating patients with erythropoietin-resistant anemias, including bone marrow failure disorders.

Experimental Procedures {#sec4}
=======================

Generation and hematopoietic differentiation of human iPSCs were performed according to previous protocols ([@bib31]).

Neural Differentiation of EBs {#sec4.1}
-----------------------------

Stem cell colonies were dissociated into single cells using accutase and cultured in suspension, without any differentiation factors, for 7 to 8 days until they formed three-dimensional multicellular aggregates. Once EBs formed, they were landed on PO/Laminin/Fibronectin-coated plates and further differentiated in N2 media supplemented with BDNF and ascorbic acid. Immunocytochemical and flow cytometry analyses were performed after an additional 7--14 days in culture.

Purification and in vitro primary culture of human cord blood CD34^+^ cells were performed according to previous protocols ([@bib33]).

Generation of Lenti- and Retroviruses and Cell Cultures {#sec4.2}
-------------------------------------------------------

Lenti- and retroviral vectors were produced by transfection of 293T and Phoenix A cells as previously described ([@bib33]). Detailed description of the constructs was provided previously ([@bib18; @bib33]). K562 cells were cultured in RPMI medium supplemented with 10% fetal bovine serum.

FACS Analysis and Sorting {#sec4.3}
-------------------------

Transduced CB CD34^+^ cells were sorted for green fluorescence (GFP) and CD34 expression after staining with an APC-conjugated anti-CD34 antibody (BD340667, Becton Dickinson), using a fluorescence-activated cell sorting (FACS) Vantage cell sorter. Cells were stained with the following antibodies: CD34-APC (BD340667, BD), CD34-PE (BD348057, BD), CD71-APC (BD561940, BD), Glycophorin A-PE (MHGLA04, Invitrogen), CD31-PE (BD555446, BD), CD34-PEcy7 (BD560710, BD), and CD45-APC (MHCD4505, Invitrogen), and analyzed by FACS. Neural progenitors were stained with Annexin V (BD556421, BD) and Ki-67 (BD558615, BD) antibodies upon fixation. Isotype-matched antibodies were utilized as negative controls.

RNA Extraction and Quantitative Real-Time PCR {#sec4.4}
---------------------------------------------

For quantitative real-time PCR, total RNA was isolated from 2 × 10^5^ cells using the RNeasy mini kit (QIAGEN), and then subjected to reverse transcription with random hexamers (SuperScript III kit, Invitrogen). Real-time PCR reactions were performed using an ABI 7500 sequence detection system. A list of PCR primers is available upon request.

Antibodies {#sec4.5}
----------

The following antibodies were used for western blot assays: the affinity purified anti-L3MBTL1 antibody (described in [@bib18]), pSMAD1/5 (9516), SMAD1 (6944P), SMAD5 (9517S), pSMAD2 (3108S), SMAD2 (5339P) (Cell Signaling Technology), HHEX (Chemicon 10071), EKLF (Abcam 49158), and HA (sc-805).

IF {#sec4.6}
--

Cultures were fixed in 4% paraformaldehyde and processed for immunocytochemistry. The following primary antibodies were used: Tuj1 (Covance MRB435P-100), Nestin (Neuromics MO15012), and TAL1 (Abcam 119754).

ChIP Assays {#sec4.7}
-----------

Approximately 4 × 10^6^ cells were used per ChIP reaction (per antibody) after crosslinking with 1% formaldehyde for 10 min at room temperature. ChIP was performed according to the previously reported methodology ([@bib54]). The associated DNA after purification was subjected to quantitative real-time PCR to detect specific DNA sequences. Quantitative results are represented as percentages to 10% DNA input. The primer sequences are available upon request.

GEP and GSEA {#sec4.8}
------------

RNA was extracted and hybridized to Affymetrix Human U133 plus 2.0 arrays, scanned, and subjected to quality control parameters. The GSEA ([@bib39]) was performed on 4,722 curated pathway gene sets from the Broad Molecular Signature Database (<http://www.broadinstitute.org/gsea/msigdb/>).

Accession Numbers {#app1}
=================

Data have been deposited in the NCBI Gene Expression Omnibus under accession number [GSE65438](ncbi-geo:GSE65438){#intref0015}.
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![KD of L3MBTL1 Primes the Hematopoietic Potential of iPSCs\
(A) Endogenous *L3MBTL1* expression was assessed in iPSCs at different time points during the mesodermal, hematopoietic, and erythroid differentiation using quantitative real-time PCR. The data represent the mean ± SD of the three independent experiments.\
(B) Strategy diagram. L3MBTL1 expression is efficiently knocked down as assessed by western blot assay in undifferentiated iPSCs. Tubulin served as the loading control.\
(C) KD of L3MBTL1 increases the expression of mesodermal-specific transcription factors while it decreases expression of key markers of endodermal and ectodermal lineages, as shown in L3MBTL1-KD undifferentiated iPSCs by qPCR compared to controls. Data indicate the relative expression level of the gene of interest, normalized by *GAPDH*. The reported fold changes have been calculated by ΔΔCt analysis versus control cells. The data represent the mean ± SD of the three independent experiments. ^∗∗^p \< 0.01 by Student's t test.\
(D) KD of L3MBTL1 increases CFU capacity of iPSC-derived HSCs. Cells from day 10 hEBs were plated in methylcellulose and colonies were scored after 15 days. The data represent the mean ± SD of the three independent experiments. ^∗^p \< 0.05 by Student's t test.\
(E) KD of L3MBTL1 promotes the emergence of early hemogenic precursor cells. EBs were harvested at day 10, prior to CD45 emergence, and analyzed by flow cytometry for CD31 and CD34 expression.\
Refer to [Figure S1](#app3){ref-type="sec"} for the characterization of the iPSC line generated from cord blood CD34^+^ cells.](gr1){#fig1}

![Impaired Development of Neural Progenitors in L3MBTL1-KD Pluripotent Stem Cells\
(A) KD of L3MBTL1 impairs the ability to form neuronal progenitor cells and neurons. Nestin and Tuj1 expression were evaluated in EBs by IF. DAPI served as control. (Top) The first line shows multiple EBs at lesser magnification (4×); the second line shows a single EB at 10× magnification. (Bottom) The impairment in neural progenitor formation of the L3MBTL1-KD EBs. The graph on the right shows the percentage of EBs containing Tuj1^+^ cells. The data represent the mean ± SD of the three independent experiments. ^∗^p \< 0.05 by Student's t test.\
(B) KD of L3MBTL1 enhances CD34 expression. (Top left) The first line shows few positive CD34^+^ EBs at low magnification (4×) in the controls; the second line shows a single EB at higher magnification (10×). (Bottom left) Increased CD34 staining in the L3MBTL1-KD EBs at 4× and 10× magnification is apparent. (Top right) Increased expression of CD34 marker (21%) in the L3MBTL1-KD cells compared to controls (3%) by FACS is shown. (Bottom right) The graph gives the percentage of EBs containing CD34^+^ cells. The data represent the mean ± SD of the three independent experiments. ^∗^p \< 0.05 by Student's t test. See also [Figure S2](#app3){ref-type="sec"}.](gr2){#fig2}

![L3MBTL1 Transcriptionally Represses SMAD5\
(A) GEP of undifferentiated L3MBTL1-KD iPSCs, compared to controls, based on microarray analysis. We utilized independent clones of iPSCs (generated from cord blood CD34+ cells), which we independently infected with lentiviral vectors expressing shRNAs against *L3MBTL1*.\
(B) mRNA expression levels of several upregulated and downregulated genes, identified by microarray analysis, was confirmed by qPCR. Data were normalized by *GAPDH* expression and shown as shRNA versus control. The data represent the mean ± SD of the three independent experiments.\
(C) GSEA for the combined set of SMAD and hematopoietic stem cells genes compared with the differentially expressed genes in L3MBTL1-KD iPSCs.\
(D) Expression levels of phospho SMAD1/5, total SMAD5, phospho SMAD2, total SMAD2, and HHEX were evaluated in L3MBTL1-KD and control iPSCs by western blot. Tubulin served as the loading control.\
(E) iPSCs were crosslinked with 1% formaldehyde and immunoprecipitated with anti-L3MBTL1 or IgG antibody (as a nonspecific control). Plotted values are relative enrichments (y axis) to 10% input and measured for sites in the *SMAD5* promoter and actin (x axis). The data represent the mean ± SD of the three independent experiments. ^∗^p \< 0.05 by Student's t test.\
(F) L3MBTL1-KD and control iPSCs were crosslinked with 1% formaldehyde and immunoprecipitated with an anti-H3K27 tri-methyl antibody or an IgG antibody (as a nonspecific control). Plotted values are relative enrichments (y axis) to 10% input and measured for sites in the *SMAD5* promoter (x axis). The data represent the mean ± SD of the three independent experiments. ^∗^p \< 0.05 by Student's t test. See also [Figure S3](#app3){ref-type="sec"}.](gr3){#fig3}

![Regulation of SMAD5 by L3MBTL1 Occurs in Erythroid Cells\
(A) KD of L3MBTL1 induces early expression of the erythroid-specific marker GlyA in iPSC-derived CD34+ cells. Representative flow cytometry analysis of iPSCs after 2 days in Epo-induced culture.\
(B) Expression levels of *EKLF*, *NF-E2*, *LMO2*, *EPOR*, and *fetal globin* gene were assessed in iPSC-derived erythroid progeny by qRT-PCR. Data were normalized by *GAPDH* expression. The data represent the mean ± SD of the three independent experiments. ^∗∗^p \< 0.01 by Student's t test.\
(C) K562 erythroleukemia cells were retrovirally transduced to express L3MBTL1-HA (blue bars) or empty MIGR1 control (gray bars), crosslinked with 1% formaldehyde, and immunoprecipitated with an anti-SMAD5 antibody or IgG antibody. Primers covering the SMAD-binding motifs ([@bib1]) across the upstream enhancer, the proximal promoter, and the intronic enhancer of the *EKLF* were utilized. Data were normalized by 10% input. The data represent the mean ± SD of the three independent experiments.\
(D) *EKLF*, *NF-E2*, *GATA-1*, *LMO2*, *EPOR*, and *BCL11A* expression levels were evaluated by qRT-PCR in L3MBTL1-KD CB CD34^+^ cells after 7 days of erythroid-supporting culture (100 ng/ml SCF and 6 U/ml EPO) compared to controls. *GAPDH* served as a housekeeping gene control. The data represent the mean ± SD of the three independent experiments. ^∗∗^p \< 0.01 by Student's t test.\
(E) Fetal globin levels were evaluated in L3MBTL1-KD CB CD34^+^ cells by western blot. Tubulin served as the loading control.\
(F) Overexpression of L3MBTL1 decreases *globin* gene mRNA levels in cord blood CD34^+^ cells, as shown by qRT-PCR. Cells were cultured for 3 days in liquid culture that supports erythroid differentiation. *GAPDH* served as the housekeeping gene. The data represent the mean ± SD of the three independent experiments. ^∗∗^p \< 0.01 by Student's t test.\
(G) Overexpression of L3MBTL1 dramatically decreases protein expression levels of gamma globin in K562 cells, as shown by western blot assay. Tubulin served as the loading control. See also [Figure S4](#app3){ref-type="sec"}.](gr4){#fig4}
